Related Experiment Video
Updated: Aug 6, 2026
A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice
Published on: September 26, 2011
An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas
1Department of Neurosurgery, Kyoto Prefectural University of Medicine.
Abstract:
Epidermal growth factor receptor (EGFR) plays an important role in the progression of malignancy in gliomas. We studied the growth inhibition of the malignant glioma cell lines using an antisense EGFR oligodeoxynucleotide enveloped with Lipofectin. At a concentration of 5 microM of the antisense EGFR oligodeoxynucleotide enveloped with Lipofectin, the proliferation of three malignant glioma cell lines was significantly inhibited (p < 0.05) compared with that of the cells exposed to 5 microM sense EGFR oligodeoxynucleotide. The activity of the tyrosine kinase and the DNA synthesis was also significantly suppressed (p < 0.05). These findings show that the antisense EGFR oligodeoxynucleotide enveloped with Lipofectin has a possibility to become a useful gene therapy against malignant gliomas.
Insights
Antisense EGFR oligodeoxynucleotide with Lipofectin effectively inhibited malignant glioma cell growth. This novel gene therapy approach suppressed proliferation, tyrosine kinase activity, and DNA synthesis in glioma cells.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Epidermal growth factor receptor (EGFR) is crucial in glioma malignancy progression.
- Targeting EGFR offers a potential therapeutic strategy for gliomas.
Purpose of the Study:
- To investigate the efficacy of antisense EGFR oligodeoxynucleotide enveloped with Lipofectin in inhibiting malignant glioma cell growth.
- To evaluate the impact of this treatment on cell proliferation, tyrosine kinase activity, and DNA synthesis.
Main Methods:
- Utilized antisense EGFR oligodeoxynucleotide complexed with Lipofectin.
- Tested on three malignant glioma cell lines.
- Compared effects against sense EGFR oligodeoxynucleotide controls.
Main Results:
- Significant inhibition of glioma cell proliferation observed at 5 microM antisense EGFR oligodeoxynucleotide (p < 0.05).
- Suppressed tyrosine kinase activity and DNA synthesis in treated cells (p < 0.05).
- Antisense treatment showed superior efficacy compared to sense controls.
Conclusions:
- Antisense EGFR oligodeoxynucleotide enveloped with Lipofectin demonstrates potent anti-glioma activity.
- This approach holds promise as a gene therapy for malignant gliomas.
- Further research is warranted to explore its clinical applications.
